We will study how drusen, which are associated with progressive vision loss in AMD, injure the retinal pigment epithelium, the tissue that nourishes and supports the light-sensing photoreceptors. In this project, we will use advanced live microscopy of the retina along with genetic and molecular approaches to study how insoluble aggregates cause mechanical stress on the RPE and how this causes atrophy and detachment of RPE cells. At each step, we will evaluate drugs that can preserve the health of the RPE and prevent RPE loss in disease models. This research will yield invaluable insight into mechanisms responsible for irreversible RPE loss in AMD and identify promising therapies to safeguard healthy vision.
There are no approved therapies for late-stage or dry AMD, which is characterized by the accumulation of large drusen and loss of focal patches of the retinal pigment epithelium (RPE). Whether drusen are a cause or consequence of AMD remains poorly understood. We will investigate how drusen-mediated mechanical stress injures the RPE and establish how this can be modulated to preserve RPE integrity. This will significantly advance the field from current observational studies on dry AMD and help identify potential therapeutics. There are no viable therapeutic options for dry AMD because the precise sequence of events leading from drusen formation to RPE loss is not known. Our studies will focus on identifying these mechanisms and evaluate small molecule drugs for their abilities to maintain RPE health. Many of which are already approved for clinical use or in clinical trials. These drugs are all orally bioavailable, which will circumvent the need for invasive intravitreal injections.
First published on: October 06, 2021
Last modified on: November 12, 2024